BioSpace News Archive

Technology platform tool, PEARL-seq™, identifies binding sites in RNA by integrating proprietary bioinformatics workflow with chemical biology techniques for the rational design of rSM therapeutics WALTHAM, Mass.--( BUSINESS WIRE )-- Arrakis Therapeutics , a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced the publication of data demonstrating the capabilities

CEL-SCI Corporation (NYSE American:CVM) , a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the LD 500 investor conference on Wednesday, September 2 nd at 10:20 a.m. ET.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announces the appointment of Stefanie Johns, Ph.D., to the position of Chief Scientific Officer, effective September 2020 . In her role, Dr. Johns will further advance Hoth’s pipeline through both preclinical and clinical stages.

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded BioCryst a new contract (75N93020C00055) totaling $44 million, and has added approximately $3 million to its existing contract (HHSN272201300017C), to support the development of galidesivir. The additional funds under these performance-base

WAT Medical Enterprise has been supporting the world’s cancer research. They donated part of the profits from selling EmeTerm on Amazon to the M.D. Anderson Cancer Center to support the development of global cancer. After making the donation in August 2019 , WAT Medical Enterprise will continue to support the cause of M.D. Anderso

Sound Pharmaceuticals, Inc. (SPI) is pleased to announce that the FDA has allowed two Phase 2 studies to begin testing ebselen (SPI-1005) in COVID-19 patients. SPI is developing SPI-1005, a novel anti-inflammatory drug which was recently shown to inhibit nCoV2 activity and viral replication. 120 adults with moderate or severe disease will

Noveome Biotherapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, announced that Larry Brown, Sc.D., the company’s Executive Vice President and Chief Scientific Officer, will co-lead a workshop entitled, “Bypassing the BBB for More Effective Delivery to the Brain” at the digital

Sage Growth Partners (SGP), a Baltimore-based healthcare research, strategy, and marketing firm, today announced that it has been retained by Pacify Health, the country’s leading telehealth app for lactation support and pediatric care

Applied UV, Inc. (NASDAQ:AUVI) today announced the pricing of its initial public offering of 1,000,000 shares of its common stock at a price of $5.00 per share.

Rodeo Therapeutics Nominates First-in-Class Oral Development Candidate for Inflammatory Bowel Disease Rodeo Therapeutics nominates Candidate RTX-1688, a first-in-class oral small molecule therapy for tissue regeneration and repair, with inflammatory bowel disease as the initial indication and platform potential in other disease settings SEATTLE--( BUSINESS WIRE )-- Rodeo Therapeutics Corporation, a company developing small-molecule therapies designe